Jump to content

Tucidinostat: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Not approved for pancreatic cancer, but rather for PTCL (by the Chinese FDA)
Removed 2 name-list-style attributes from cite entries that match that of "cs1 config" template to exclude the article from Category:CS1 maint: overridden setting.
 
(38 intermediate revisions by 31 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}
{{Infobox drug
{{Infobox drug
| drug_name =
| drug_name =
| IUPAC_name = ''N''-(2-Amino-5-fluorophenyl)-4-<nowiki>[[[</nowiki>1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide
| IUPAC_name = ''N''-(2-Amino-4-fluorophenyl)-4-<nowiki>[[[</nowiki>(''E'')-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
| image = Chidamide.svg
| image = Tucidinostat.svg
| alt =
| alt =
| caption =
| caption =


<!-- Clinical data -->
<!-- Clinical data -->
| tradename = Epidaza
| tradename = Epidaza, Hiyasta
| Drugs.com =
| Drugs.com =
| MedlinePlus =
| MedlinePlus =
Line 34: Line 35:


<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 743420-02-2
| CAS_number = 1616493-44-7
| ATCvet =
| ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_prefix = None <!-- Scheduled to be L01XH06 in 2025 -->
| ATC_suffix =
| ATC_suffix =
| UNII_Ref = {{fdacite|correct|FDA}}
⚫
| PubChem =
| UNII = 87CIC980Y0
⚫
| DrugBank =
⚫
| PubChem = 12136798
⚫
| DrugBank = 06334
| KEGG = D10993
| ChEMBL = 3621988
| ChemSpiderID = 7976319
| synonyms = Chidamide, HBI-8000


<!-- Chemical data -->
<!-- Chemical data -->
| C=22 | H=19 | F=1 | N=4 | O=2
| chemical_formula = C<sub>22</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>
⚫
| smiles = C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N
| molecular_weight = 390.4 g/mol
| StdInChI = 1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+
⚫
| smiles = NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1
| StdInChIKey = SZMJVTADHFNAIS-BJMVGYQFSA-N
}}
}}


'''Tucidinostat''' ([[International Nonproprietary Name|INN]], also known as '''chidamide''' and sold under the brand names '''Epidaza''' and '''Hiyasta''') is a [[histone deacetylase inhibitor]] (HDI) developed in China.<ref name=SA2015>{{cite web | first = Derek | last = Lowe |url=http://seekingalpha.com/article/3055626-chinas-first-homegrown-pharma |title=China's First Homegrown Pharma. |date=April 2015 | work = Seeking Alpha }}</ref> It was also known as '''HBI-8000'''.<ref name=FBT2016/> It is a [[benzamide]] HDI and inhibits Class I [[HDAC1]], [[HDAC2]], [[HDAC3]], as well as Class IIb [[HDAC10]].<ref>{{cite web | url = http://www.prnewswire.com/news-releases/huya-bioscience-international-grants-an-exclusive-license-for-hbi-8000-in-japan-and-other-asian-countries-to-eisai-300212563.html | title = HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai | date = February 2016 | publisher = PR Newswire Association LLC }}</ref>
⚫
'''Chidamide''' ('''Epidaza''') is an [[HDAC inhibitor]] developed wholly in China that shows potential in treating [[pancreatic cancer]].<ref>{{cite journal|last1=Qiao|first1=Z|title=Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.|journal=Biochem Biophys Res Commun.|date=2013-04-26|volume=434|issue=1|pages=95–101|doi=10.1016/j.bbrc.2013.03.059|pmid=23541946}}</ref><ref>{{cite journal|last1=Guha|first1=Malini|title=HDAC inhibitors still need a home run, despite recent approval|journal=Nature Reviews Drug Discovery|date=2015-04-01|volume=14|pages=225–226|doi=10.1038/nrd4583|url=http://www.nature.com/nrd/journal/v14/n4/full/nrd4583.html}}</ref><ref>{{cite news|last1=Wang|first1=Shirley S.|title=A New Cancer Drug, Made in China|url=http://www.wsj.com/articles/a-new-cancer-drug-made-in-china-1428004715|accessdate=13 April 2015|agency=The Wall Street Journal|date=2015-04-02}}</ref>


Tucidinostat is approved by the Chinese FDA for relapsed or refractory [[peripheral T-cell lymphoma]] (PTCL) and has [[orphan drug]] status in Japan.<ref name="FBT2016">{{cite press release | title = Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China | url = https://www.prnewswire.com/news-releases/chipscreen-biosciences-announces-cfda-approval-of-chidamide-epidaza-for-ptcls-in-china-300017763.html | publisher = PR Newswire Association LLC }}</ref>{{better source|date=March 2016}} In Japan, it was approved for relapsed or refractory [[adult T-cell leukemia-lymphoma]] (ATLL) treatment in June 2021.<ref>{{cite web | url = https://www.meiji.com/global/news/2021/pdf/210624_01.pdf | title = Marketing Approval of HBI-8000 (Tucidinostat) for Relapsed or Refractory ATLL Treatment in Japan }}</ref>
{{As of|April 2015}} it is only approved in China.<ref>{{cite web |url=http://seekingalpha.com/article/3055626-chinas-first-homegrown-pharma |title=China's First Homegrown Pharma. |date=April 2015}}</ref>


⚫
Tucidinostat is being researched as a treatment for [[pancreatic cancer]].<ref name=Qiao2013>{{cite journal | vauthors = Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, Sun L, He Y, Ge Y, Yu Q | display-authors = 6 | title = Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells | journal = Biochemical and Biophysical Research Communications | volume = 434 | issue = 1 | pages = 95–101 | date = April 2013 | pmid = 23541946 | doi = 10.1016/j.bbrc.2013.03.059 }}</ref><ref name=Guha2015>{{cite journal | vauthors = Guha M | s2cid = 36758974 | title = HDAC inhibitors still need a home run, despite recent approval | journal = Nature Reviews. Drug Discovery | volume = 14 | issue = 4 | pages = 225–6 | date = April 2015 | pmid = 25829268 | doi = 10.1038/nrd4583 }}</ref><ref>{{cite news|last1=Wang|first1=Shirley S. |title=A New Cancer Drug, Made in China|url=https://www.wsj.com/articles/a-new-cancer-drug-made-in-china-1428004715|access-date=13 April 2015|agency=The Wall Street Journal|date=2015-04-02}}</ref> However, it is not [[US FDA]] approved for the treatment of pancreatic cancer.
Is NOT approved for the treatment of pancreatic cancer. Is approved by the Chinese FDA for relapsed or refractory peripheral T cell lymphoma.


==References==
== References ==
{{reflist}}
{{Reflist}}

{{HDAC inhibitors}}


[[Category:Histone deacetylase inhibitors]]
[[Category:Histone deacetylase inhibitors]]
[[Category:Pyridines]]
[[Category:3-Pyridyl compounds]]
[[Category:Benzamides]]
[[Category:Benzamides]]
[[Category:Anilides]]
[[Category:Anilides]]
[[Category:Fluoroarenes]]
[[Category:Fluoroarenes]]


{{pharm-stub}}

Latest revision as of 04:51, 8 February 2024

Tucidinostat
Clinical data
Trade namesEpidaza, Hiyasta
Other namesChidamide, HBI-8000
ATC code
  • None
Identifiers
  • N-(2-Amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H19FN4O2
Molar mass390.418 g·mol−1
3D model (JSmol)
  • C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N
  • InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+
  • Key:SZMJVTADHFNAIS-BJMVGYQFSA-N

Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China.[1] It was also known as HBI-8000.[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.[3]

Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.[2][better source needed] In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.[4]

Tucidinostat is being researched as a treatment for pancreatic cancer.[5][6][7] However, it is not US FDA approved for the treatment of pancreatic cancer.

References

[edit]
  1. ^ Lowe D (April 2015). "China's First Homegrown Pharma". Seeking Alpha.
  2. ^ a b "Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China" (Press release). PR Newswire Association LLC.
  3. ^ "HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai". PR Newswire Association LLC. February 2016.
  4. ^ "Marketing Approval of HBI-8000 (Tucidinostat) for Relapsed or Refractory ATLL Treatment in Japan" (PDF).
  5. ^ Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, et al. (April 2013). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochemical and Biophysical Research Communications. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
  6. ^ Guha M (April 2015). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews. Drug Discovery. 14 (4): 225–6. doi:10.1038/nrd4583. PMID 25829268. S2CID 36758974.
  7. ^ Wang SS (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tucidinostat&oldid=1204848720"